Clinically relevant mutations in the ABCG2 transporter uncovered by genetic analysis linked to erythrocyte membrane

Boglárka Zámbó1, Zsuzsa Bartos1, Orsolya Mózner1

  • 1Institute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Magyar Tudosok krt. 2, Budapest, 1117, Hungary.

Scientific Reports
|May 12, 2018
PubMed

Insights

A novel ABCG2 mutation (ABCG2-M71V) reduces transporter protein expression, impacting gout and drug resistance. This discovery highlights the need for personalized medicine considering genetic variations in membrane proteins.

Area of Science:

  • Biochemistry and Molecular Biology
  • Pharmacogenomics
  • Membrane Transport Proteins

Background:

  • The ATP-binding cassette subfamily G member 2 (ABCG2) is a crucial transporter protein involved in xenobiotic and endobiotic transport.
  • ABCG2 dysfunction is implicated in conditions such as gout and multidrug resistance in cancer.
  • Reduced ABCG2 expression has been observed in erythrocyte membranes of gout patients.

Purpose of the Study:

  • To identify novel mutations in ABCG2 associated with altered protein expression.
  • To investigate the functional consequences of identified mutations on ABCG2 transport activity.
  • To explore potential therapeutic strategies for ABCG2-related disorders.

Main Methods:

  • Analysis of ABCG2 expression in erythrocyte membranes from healthy volunteers and gout patients.
  • Genetic screening to identify ABCG2 mutations based on protein expression levels.
  • In vitro cellular expression studies to assess the impact of mutations on protein expression and function.
  • Molecular dynamics simulations to elucidate the structural and dynamic effects of mutations.
  • Testing of small molecules for their ability to correct mutant ABCG2 expression.

Main Results:

  • A novel, relatively frequent ABCG2 mutation, ABCG2-M71V, was identified.
  • Cellular expression studies revealed that ABCG2-M71V leads to reduced protein expression but retains transporter capability.
  • Molecular dynamics simulations suggested altered protein dynamics for the ABCG2-M71V mutant.
  • Therapeutically relevant small molecules demonstrated the ability to correct ABCG2-M71V expression in vitro.

Conclusions:

  • The ABCG2-M71V mutation is a significant finding with implications for gout and cancer treatment.
  • Genetic analysis combined with protein expression profiling is a valuable approach for discovering clinically relevant membrane protein mutations.
  • Personalized medicine strategies should incorporate the identification of specific ABCG2 mutations for tailored therapeutic interventions.

Related Concept Videos

Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
9.7K
Mutation, Gene Flow, and Genetic Drift01:09

Mutation, Gene Flow, and Genetic Drift

In a population that is not at Hardy-Weinberg equilibrium, the frequency of alleles changes over time. Therefore, any deviations from the five conditions of Hardy-Weinberg equilibrium can alter the genetic variation of a given population. Conditions that change the genetic variability of a population include mutations, natural selection, non-random mating, gene flow, and genetic drift (small population size).
64.6K
Protein Transport to the Inner Chloroplast Membrane01:18

Protein Transport to the Inner Chloroplast Membrane

Proteins targeted to the inner chloroplast membrane, or plastid proteins, are transported by two general pathways: the stop-transfer and the re-insertion or post-import pathways. Most plastid proteins carry N-terminal transit sequences and internal import sequences targeting it to the specific chloroplast subcompartment. Proteins targeted by the stop-transfer pathway have internal hydrophobic sequences that inhibit their translocation into the stroma. As a result, these precursors are arrested...
2.5K
Protein Transport into the Inner Mitochondrial Membrane01:34

Protein Transport into the Inner Mitochondrial Membrane

Nuclear encoded mitochondrial precursors are imported to the inner membrane in a multistep process involving two separate translocons, TIM22 and TIM23. TIM23 is a cation-selective pore that remains closed by the N terminal segment of the protein. Negative charges on the TIM23 act as a receptor for the incoming precursor, pulling the positively charged matrix-targeting sequence for peptide insertion and translocation.
Transport of mitochondrial precursors across the TIM23 channel is driven by...
5.0K
Introduction to Membrane Proteins01:16

Introduction to Membrane Proteins

The cell membrane, or plasma membrane, is an ever-changing landscape. It is described as a fluid mosaic where various macromolecules are embedded in the phospholipid bilayer. Among the macromolecules are proteins. The protein content varies across cell types. For example, mitochondrial inner membranes contain ~76% protein content, while myelin contains ~18% protein content. Individual cells contain many types of membrane proteins—red blood cells contain over 50—and different cell...
81.6K
Protein Transport to the Outer Chloroplast Membrane01:11

Protein Transport to the Outer Chloroplast Membrane

Chloroplast outer membrane proteins encoded by the nucleus are synthesized in the cytosol. Soon after synthesis, they bind cytosolic factors such as 14-3-3 protein and the Hsp70 chaperones that keep these precursors in an unfolded state until their translocation.
Two models describe the mechanism of precursor recognition and entry across the outer membrane through the TOC complex. Model 1 suggests the newly synthesized precursor binds to the TOC receptor 159 and forms a complex.
2.4K